$PCRX
Pacira Biosciences Inc Stock $pcrx

$pcrx Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000110465913060304 Filed on August 06, 2013

Income Statement

Concept	2013 Q2	2012 Q2
Revenue	$17.14M	$12.34M
YoY Change	38.86%	239.49%
Cost Of Revenue	$10.21M	$6.685M
YoY Change	52.79%	114.61%
Gross Profit	$6.927M	$5.659M
YoY Change	22.41%	986.18%
Gross Profit Margin	40.41%	45.84%
Selling, General & Admin	$14.08M	$10.41M
YoY Change	35.22%	133.16%
% of Gross Profit	203.26%	184.01%
Research & Development	$4.857M	$1.872M
YoY Change	159.46%	-59.18%
% of Gross Profit	70.12%	33.08%
Depreciation & Amortization	$800.0K	$0.00
YoY Change		-100.0%
% of Gross Profit	11.55%	0.0%
Operating Expenses	$29.15M	$18.97M
YoY Change	53.67%	55.91%
Operating Profit	-$12.01M	-$6.626M
YoY Change	81.26%	-22.33%
Interest Expense	$1.914M	$494.0K
YoY Change	287.45%	-26.92%
% of Operating Profit
Other Income/Expense, Net	-$2.021M	-$1.670M
YoY Change	21.02%	619.83%
Pretax Income	-$14.03M	-$8.296M
YoY Change	69.13%	-5.73%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$14.03M	-$8.296M
YoY Change	69.13%	-5.33%
Net Earnings / Revenue	-81.86%	-67.21%
Basic Earnings Per Share	-$0.42	-$0.27
Diluted Earnings Per Share	-$0.42	-$0.27
COMMON SHARES
Basic Shares Outstanding	33.08M shares	30.95M shares
Diluted Shares Outstanding	33.08M shares	30.95M shares

Balance Sheet

Concept	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$96.00M	$84.30M
YoY Change	13.88%	78.6%
Cash & Equivalents	$8.626M	$21.45M
Short-Term Investments	$87.30M	$62.80M
Other Short-Term Assets	$3.600M	$3.200M
YoY Change	12.5%	-8.57%
Inventory	$14.22M	$9.299M
Prepaid Expenses
Receivables	$7.756M	$3.200M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$121.5M	$100.1M
YoY Change	21.4%	86.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$42.07M	$29.97M
YoY Change	40.38%	21.81%
Goodwill	$8.980M	$8.000M
YoY Change	12.25%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.712M	$600.0K
YoY Change	518.67%	-45.45%
Total Long-Term Assets	$56.94M	$42.78M
YoY Change	33.11%	27.69%
TOTAL ASSETS
Total Short-Term Assets	$121.5M	$100.1M
Total Long-Term Assets	$56.94M	$42.78M
Total Assets	$178.4M	$142.9M
YoY Change	24.9%	64.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.712M	$400.0K
YoY Change	328.0%	-92.16%
Accrued Expenses	$12.26M	$9.300M
YoY Change	31.83%	158.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$900.0K	$1.200M
YoY Change	-25.0%	-80.95%
Total Short-Term Liabilities	$15.84M	$15.24M
YoY Change	3.93%	-12.94%
LONG-TERM LIABILITIES
Long-Term Debt	$96.89M	$25.90M
YoY Change	274.1%	14.6%
Other Long-Term Liabilities	$2.743M	$7.200M
YoY Change	-61.9%	-70.12%
Total Long-Term Liabilities	$99.64M	$33.10M
YoY Change	201.01%	-29.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.84M	$15.24M
Total Long-Term Liabilities	$99.64M	$33.10M
Total Liabilities	$119.3M	$48.35M
YoY Change	146.73%	-24.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$269.7M
YoY Change
Common Stock	$33.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.000K
YoY Change
Treasury Stock Shares	1.065K shares	1.065K shares
Shareholders Equity	$59.14M	$94.51M
YoY Change
Total Liabilities & Shareholders Equity	$178.4M	$142.9M
YoY Change	24.86%	64.06%

Cashflow Statement

Concept	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$14.03M	-$8.296M
YoY Change	69.13%	-5.33%
Depreciation, Depletion And Amortization	$800.0K	$0.00
YoY Change		-100.0%
Cash From Operating Activities	-$13.31M	-$20.22M
YoY Change	-34.17%	85.16%
INVESTING ACTIVITIES
Capital Expenditures	-$1.740M	-$4.370M
YoY Change	-60.18%	261.16%
Acquisitions
YoY Change
Other Investing Activities	-$3.780M	-$43.18M
YoY Change	-91.25%	118.52%
Cash From Investing Activities	-$5.520M	-$47.54M
YoY Change	-88.39%	126.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$62.90M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.180M	64.00M
YoY Change	-98.16%
NET CHANGE
Cash From Operating Activities	-13.31M	-20.22M
Cash From Investing Activities	-5.520M	-47.54M
Cash From Financing Activities	1.180M	64.00M
Net Change In Cash	-17.65M	-3.760M
YoY Change	369.41%	-88.21%
FREE CASH FLOW
Cash From Operating Activities	-$13.31M	-$20.22M
Capital Expenditures	-$1.740M	-$4.370M
Free Cash Flow	-$11.57M	-$15.85M
YoY Change	-27.0%	63.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
CY2013Q1	pcrx	Proceeds From Sale Of Unused Net Operating Losses ProceedsFromSaleOfUnusedNetOperatingLosses	400000	USD
	pcrx	Minimum Period For Which Available Cash And Cash Equivalents Short Term Investments And Revenue Will Be Sufficient To Meet Expenses MinimumPeriodForWhichAvailableCashAndCashEquivalentsShortTermInvestmentsAndRevenueWillBeSufficientToMeetExpenses	P12M
CY2012Q4	us-gaap	Long Term Debt LongTermDebt	25191000	USD
CY2012Q4	pcrx	Royalty Interest Obligation RoyaltyInterestObligation	1680000	USD
CY2012Q4	pcrx	Long Term Debt Including Royalty Interest Obligation LongTermDebtIncludingRoyaltyInterestObligation	26871000	USD
CY2013Q2	pcrx	Royalty Interest Obligation Current RoyaltyInterestObligationCurrent	891000	USD
CY2013Q2	pcrx	Royalty Interest Obligation Noncurrent RoyaltyInterestObligationNoncurrent	584000	USD
CY2013Q2	pcrx	Royalty Interest Obligation RoyaltyInterestObligation	1475000	USD
CY2013Q2	pcrx	Long Term Debt Including Royalty Interest Obligation LongTermDebtIncludingRoyaltyInterestObligation	98367000	USD
CY2013Q2	pcrx	Long Term Debt Noncurrent Gross LongTermDebtNoncurrentGross	120000000	USD
CY2013Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	23108000	USD
CY2013Q2	us-gaap	Long Term Debt LongTermDebt	96892000	USD
CY2012Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	30897000	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	28000	USD
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	1000	USD
CY2013Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	87317000	USD
CY2013Q2	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	50000	USD
CY2013Q2	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	37000	USD
	pcrx	Number Of Major Customers NumberOfMajorCustomers	4	item
CY2012	pcrx	Number Of Major Customers NumberOfMajorCustomers	4	item
CY2013Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3427000	USD
CY2013Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6529000	USD
CY2013Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4265000	USD
CY2013Q2	us-gaap	Inventory Net InventoryNet	14221000	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4081000	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5979000	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2017000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	12077000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	50719000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11603000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39116000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	52636000	USD
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10571000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42065000	USD
CY2013Q2	us-gaap	Depreciation Depreciation	800000	USD
CY2012Q2	us-gaap	Depreciation Depreciation	900000	USD
CY2013Q2	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	300000	USD
CY2012Q2	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	500000	USD
CY2012Q2	pcrx	Payment Obligation Arising Due To First Commercial Sale Of Product In Connection With Acquisition PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition	10000000	USD
CY2012Q2	pcrx	Contingent Payment Obligation Established For Sale Of Product In Connection With Acquisition ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition	2000000	USD
CY2012Q2	us-gaap	Goodwill Goodwill	8000000	USD
CY2013Q2	pcrx	Goodwill Recorded For Earn Out Payments GoodwillRecordedForEarnOutPayments	1000000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3208000	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2183000	USD
CY2013Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2012Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1026000	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	754000	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	322000	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	81000	USD
CY2012Q4	pcrx	Long Term Debt Noncurrent Gross LongTermDebtNoncurrentGross	27500000	USD
CY2012Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2309000	USD
CY2012Q4	pcrx	Royalty Interest Obligation Current RoyaltyInterestObligationCurrent	823000	USD
CY2012Q4	pcrx	Royalty Interest Obligation Noncurrent RoyaltyInterestObligationNoncurrent	857000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2225000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4450000	USD
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1040000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1751000	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	5204537	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4830791	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	373746	shares
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-14031000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-8296000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37169000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20190000	USD
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33083000	shares
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33083000	shares
CY2012Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30954000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32896000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28160000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32896000	shares
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30954000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28160000	shares
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.13
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	2224000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4765000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4978000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5130000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	5072000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	13734000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	35903000	USD
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10126000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1523000	USD
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	30924000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4352000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1920000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	60922000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	8297000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	511000	USD
CY2012Q4	us-gaap	Assets Assets	112054000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2569000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9792000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	972000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14156000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25191000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3720000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2275000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	46199000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	33000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	298317000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-232520000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	27000	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2000	USD
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	65855000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	112054000	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	178430000	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	59142000	USD
CY2013Q2	us-gaap	Liabilities Liabilities	119288000	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	15835000	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	121490000	USD
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33230104	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32624049	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33229039	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32622984	shares
CY2013Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	1065	shares
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1065	shares
CY2012Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4981000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	5427000	USD
CY2012Q2	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	6600000	USD
	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	13090000	USD
CY2012Q2	us-gaap	Royalty Revenue RoyaltyRevenue	763000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	1631000	USD
CY2013Q2	us-gaap	Revenues Revenues	17141000	USD
CY2012Q2	us-gaap	Revenues Revenues	12344000	USD
	us-gaap	Revenues Revenues	28728000	USD
	us-gaap	Revenues Revenues	20148000	USD
CY2012Q2	us-gaap	Cost Of Revenue CostOfRevenue	6685000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	13180000	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1872000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3166000	USD
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10413000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21565000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	29151000	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	18970000	USD
	us-gaap	Operating Expenses OperatingExpenses	59384000	USD
	us-gaap	Operating Expenses OperatingExpenses	37911000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12010000	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6626000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30656000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17763000	USD
CY2012Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	68000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	131000	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	494000	USD
	us-gaap	Interest Expense InterestExpense	1008000	USD
CY2012Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1062000	USD
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2427000	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1062000	USD
CY2012Q2	us-gaap	Royalty Expense RoyaltyExpense	143000	USD
	us-gaap	Royalty Expense RoyaltyExpense	425000	USD
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-39000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-63000	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2021000	USD
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1670000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6955000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.72
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33083289	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30953635	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32896294	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28160471	shares
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14062000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-31000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-14000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37183000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	83000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	83000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20107000	USD
CY2012Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	81000	USD
CY2012Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	81000	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8215000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2785000	USD
	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	-116000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	310000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1751000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	548000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1101000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8054000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-430000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1256000	USD
	pcrx	Increase Decrease In Royalty Interest Obligation IncreaseDecreaseInRoyaltyInterestObligation	322000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-42000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-12483000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-37774000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7267000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	52772000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	20000000	USD
	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	10034000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-50072000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	383000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	27500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	62855000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	26250000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1365000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	63123000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-24723000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-1500000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-61774000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-27099000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	120000000	USD
	us-gaap	Interest Paid InterestPaid	2282000	USD
	pcrx	Class Of Warrant Or Right Value Of Warrant Issued With Debt ClassOfWarrantOrRightValueOfWarrantIssuedWithDebt	1354000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8626000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46168000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21445000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2064000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4450000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-14000	USD
	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	23956000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001396814
	dei	Entity Registrant Name EntityRegistrantName	Pacira Pharmaceuticals, Inc.
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33315669	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2013Q2	pcrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	2824000	shares
CY2012Q2	pcrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	1334000	shares
	pcrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	2394000	shares
	pcrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	1307000	shares
	us-gaap	Depreciation Depreciation	1700000	USD
	us-gaap	Depreciation Depreciation	1800000	USD
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	600000	USD
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	900000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000	USD
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	998000	USD
CY2013Q2	us-gaap	Short Term Investments ShortTermInvestments	87330000	USD
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7756000	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2559000	USD
CY2013Q2	us-gaap	Goodwill Goodwill	8980000	USD
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3712000	USD
CY2013Q2	us-gaap	Assets Assets	178430000	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1712000	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12260000	USD
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	972000	USD
CY2013Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	96892000	USD
CY2013Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3234000	USD
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2743000	USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	33000	USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	328787000	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-269689000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	13000	USD
CY2013Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2000	USD
CY2013Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	16278000	USD
CY2013Q2	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	243000	USD
CY2013Q2	us-gaap	Royalty Revenue RoyaltyRevenue	620000	USD
CY2013Q2	us-gaap	Cost Of Revenue CostOfRevenue	10214000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4857000	USD
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14080000	USD
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	72000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	145000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	1914000	USD
	us-gaap	Interest Expense InterestExpense	3433000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3398000	USD
CY2013Q2	us-gaap	Royalty Expense RoyaltyExpense	161000	USD
	us-gaap	Royalty Expense RoyaltyExpense	247000	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-18000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-22000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14031000	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8296000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37611000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20190000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-442000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	27113000	USD
	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	486000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	1129000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	21605000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10762000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27017000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-31000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-14000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2717000	USD
	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	216000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1890000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-31000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4450000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-525000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3403000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2144000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	711000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3260000	USD
	pcrx	Increase Decrease In Royalty Interest Obligation IncreaseDecreaseInRoyaltyInterestObligation	205000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	532000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-486000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4672000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	87220000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	30800000	USD
	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	682000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2064000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	27500000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	7191000	USD
	us-gaap	Interest Paid InterestPaid	846000	USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2013Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD

Files In Submission

Name	View Source	Status
0001104659-13-060304-index-headers.html	Edgar Link	pending
0001104659-13-060304-index.html	Edgar Link	pending
0001104659-13-060304.txt	Edgar Link	pending
0001104659-13-060304-xbrl.zip	Edgar Link	pending
a13-13640_110q.htm	Edgar Link	pending
a13-13640_1ex31d1.htm	Edgar Link	pending
a13-13640_1ex31d2.htm	Edgar Link	pending
a13-13640_1ex32d1.htm	Edgar Link	pending
a13-13640_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
pcrx-20130630.xml	Edgar Link	completed
pcrx-20130630.xsd	Edgar Link	pending
pcrx-20130630_cal.xml	Edgar Link	unprocessable
pcrx-20130630_def.xml	Edgar Link	unprocessable
pcrx-20130630_lab.xml	Edgar Link	unprocessable
pcrx-20130630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R41.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R42.xml	Edgar Link	unprocessable
R43.htm	Edgar Link	pending
R43.xml	Edgar Link	unprocessable
R44.htm	Edgar Link	pending
R44.xml	Edgar Link	unprocessable
R45.htm	Edgar Link	pending
R45.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCRX
Pacira Biosciences Inc Stock $pcrx

2013 Q2 Form 10-Q Financial Statement

#000110465913060304 Filed on August 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX Pacira Biosciences Inc Stock $pcrx

2013 Q2 Form 10-Q Financial Statement

#000110465913060304 Filed on August 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX
Pacira Biosciences Inc Stock $pcrx